Search

To investigate the relationship between changes in core and skin surface temperature and extubation time in patients following normothermic cardiopulmonary bypass (CPB).Prospective observational study.Intensive care unit (ICU) of a university hospital.Patients admitted to the ICU after cardiac surgery.None.Thirty-two patients undergoing cardiac surgery with the use of normothermic CPB were studied. In the ICU, urinary bladder temperature and skin surface temperature gradient (forearm temperature minus fingertip temperature) were measured at 30-min intervals for 10 h postoperatively. Every half-hour an anaesthesiologist, blinded to temperature measurements, checked the possibility of extubation. On arrival in the ICU the mean skin surface temperature gradient of the patients was 1.9+/-1.6 degrees C, indicating vasoconstriction of the dermal vessels (0 degrees C = vasoconstriction,0 degrees C = vasodilation) while the mean urinary bladder temperature was 36.8+/-0.4 degrees C. The change from thermoregulatory vasoconstriction to vasodilation (skin surface temperature gradient of 0 degrees C) was 137+/-49 min after arrival in the ICU. The mean time until extubation was 135+/-55 min after arrival in the ICU. There was a linear relation between a temperature gradient of 0 degrees C and extubation time, r(2)=0.49. Later, 181+/-67 min after arrival in the ICU, the urinary bladder temperature reached its maximum of 38.2+/-0.6 degrees C.This study demonstrates that the transition period from peripheral vasoconstriction to vasodilation provides an opportunity for postoperative extubation.

Objectives: To test the hypothesis whether in patients undergoing liver transplantation the antioxidant tirilazad mesylate can reduce hepatic ischaemia-reperfusion injury and improve postoperative outcome. Design: Prospective, randomised, placebo controlled trial. Setting: University hospital. Patients: 20 patients were randomised to receive either tirilazad mesylate or placebo (saline). Interventions: Patients in the tirilazad group (n = 10) received four intravenous infusions of tirilazad at 6-h intervals (men 3 mg/kg, women 3.75 mg/kg) after the induction of anaesthesia. The other patients (n = 10) served as controls. Measurements and results: Plasma levels of malonaldehyde (MDA) were determined after the induction of anaesthesia prior to the infusion of tirilazad (baseline), during the anhepatic period, and 5 min and 24 h after reperfusion. Postoperatively, alanine aminotransferase, aspartate aminotransferase, prothrombin time, and serum cholinesterase were determined daily for 1 week. Compared to baseline, plasma MDA levels did not significantly change during the anhepatic period and after reperfusion and they did not differ between groups. Postoperative liver enzymes and prothrombin time did not differ between groups, but on the first (p = 0.03) and second (p = 0.01) postoperative day cholinesterase levels were significantly higher in tirilazad-treated patients than in control patients. For neither length of stay in the intensive care unit nor hospital stay were any differences observed between groups. Conclusions: In patients undergoing liver transplantation, tirilazad does not improve overall outcome. Whether the higher cholinesterase levels on the first 2 postoperative days in tirilazad treated patients indicates an earlier recovery of liver function remains to be tested.